Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/16/2025

Use of Tobramycin Eyedrops in Pediatric Patients

Safety and Efficacy Considerations

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines strongly recommend using topical or local applications of aminoglycosides rather than intravenous administration when feasible, specifically because this approach minimizes systemic exposure and nephrotoxicity risk 1, 2
  • Systemic aminoglycosides (IV tobramycin) carry significant nephrotoxicity and ototoxicity risks in neonates, with eighth cranial nerve damage documented with streptomycin and kanamycin 3
  • Ophthalmic drops deliver medication directly to the infection site with negligible blood levels, avoiding the renal and auditory toxicity concerns associated with systemic aminoglycosides 1, 2
  • The concern about "impaired renal function" is primarily relevant for systemic aminoglycoside administration, not topical ophthalmic use, as noted by the Kidney International guidelines 1, 4